Opportunities and challenges of mRNA technologies in development of dengue virus vaccine
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.
TL;DRThis review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines and aims to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts. (Semantic Scholar)